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Introduction
Lung grafts have the worst overall survival of  all solid organs (1). A complex and unique immunoregu-
latory network, that differs significantly from other organ grafts, is at least partially responsible for such 
poor long-term outcomes. Clinically accepted immunosuppression regimens, that globally downregulate or 
even temporarily ablate the adaptive immune response, result in acceptable long-term survival of  heart and 
kidney grafts but yield close to a 50% lung allograft loss 5 years after engraftment (2). We and others have 
suggested that unique immunoregulatory pathways that contribute to acceptance of  this mucosal barrier 
organ may require a different strategy for long-term graft survival (3, 4). For example, depletion of  CD8+ T 
cells as well as other proinflammatory cells contributes to the acceptance of  most transplanted organs but 
prevents lung allograft acceptance (5, 6).
Along those lines, we have recently demonstrated that eosinophils, a granulocytic population long con-
sidered deleterious for long-term graft function, play a critical role in costimulatory blockade–mediated 
(CSB-mediated) induction of  lung allograft tolerance (7). The role of  this cell population in the absence of  
CSB or its mechanism(s) of  immunosuppression remain unknown. Here we demonstrate that eosinophils 
play a unique role in the downregulation of  the lung alloimmune response even in the absence of  traditional 
or CSB-mediated immunosuppression. Thus, unlike the case for other solid organs, eosinophils play an 
exclusive and solely tolerogenic role in the lung allograft (8). Mechanistically, we demonstrate that Th1-po-
larized eosinophils inhibit CD8+ T cell proliferation by interfering with T cell receptor/CD3 (TCR/CD3) 
subunit association and signal transduction in an inducible NOS–dependent (iNOS-dependent) manner. We 
further show that PD-L1–dependent eosinophil–T cell contact is critical for eosinophil suppressive function.
Despite the accepted notion that granulocytes play a universally destructive role in organ and 
tissue grafts, it has been recently described that eosinophils can facilitate immunosuppression-
mediated acceptance of murine lung allografts. The mechanism of eosinophil-mediated tolerance, 
or their role in regulating alloimmune responses in the absence of immunosuppression, remains 
unknown. Using lung transplants in a fully MHC-mismatched BALB/c (H2d) to C57BL/6 (H2b) 
strain combination, we demonstrate that eosinophils downregulate T cell–mediated immune 
responses and play a tolerogenic role even in the absence of immunosuppression. We further 
show that such downregulation depends on PD-L1/PD-1–mediated synapse formation between 
eosinophils and T cells. We also demonstrate that eosinophils suppress T lymphocyte responses 
through the inhibition of T cell receptor/CD3 (TCR/CD3) subunit association and signal transduction 
in an inducible NOS–dependent manner. Increasing local eosinophil concentration, through 
administration of intratracheal eotaxin and IL-5, can ameliorate alloimmune responses in the lung 
allograft. Thus, our data indicate that eosinophil mobilization may be utilized as a novel means of 
lung allograft–specific immunosuppression.
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Results
E1-polarized eosinophils accumulate in tolerant and rejecting lung allografts. It has been demonstrated by us as well 
as others that eosinophils may alter their phenotype and function based on the local environment (7, 9, 10). 
Since costimulation plays a critical role in T cell cytokine production and environmental polarization (11, 
12), we examined the possibility that eosinophils may lose their tolerogenic properties in the absence of  CSB 
immunosuppression. Cytokine expression was examined in BALB/c (H2d) lung allografts transplanted into 
fully MHC-mismatched C57BL/6 (B6) (H2b) recipient mice. In the absence of  immunosuppression, lung 
allografts had higher levels of  Th1-polarizing cytokines IFN-γ and TNF-α than did CSB-treated accepting 
lung grafts (Figure 1A). Limited amounts of  Th2-polarizing cytokines IL-4, IL-13, IL-33, and GM-CSF 
were evident in lung allografts treated with or without CSB immunosuppression (Supplemental Figure 1A; 
supplemental material available online with this article; https://doi.org/10.1172/jci.insight.128241DS1). 
We next evaluated lung-resident eosinophils from both CSB-treated and nonimmunosuppressed grafts. 
Based on a previously identified eosinophil polarization phenotype (7), we noted higher levels of  Th1-de-
fining (or E1-defining) features, such as CXCL9, CXCL10, CXCL11, and iNOS in eosinophils isolated 
from rejecting compared with CSB-treated lung allografts (Figure 1A). In no group was Th2 (or E2) polar-
ization of  eosinophils detected (Supplemental Figure 1A). Flow cytometric characterization demonstrated 
an absence of  MHC II and costimulatory molecules such as CD80, CD86, and CD40. However, there 
were high levels of  recipient-derived MHC I (H2Kb), PD-L1, and CD101 on lung-resident eosinophils in 
the absence of  CSB (Figure 1B). Notably, we did not detect BALB/c-derived H2d-MHC on graft-resident 
eosinophils, indicating a lack of  “cross-dressing” or antigen swapping for donor derived–antigens (ref. 13 
and Supplemental Figure 1B). Thus, while eosinophils from rejecting lungs resembled those from accepting 
lungs in some aspects, we did observe some differences. It is thus possible that in the absence of  immu-
nosuppression, eosinophils may contribute to graft rejection rather than acceptance, specifically because 
CD101 expression has been previously associated with an inflammatory eosinophil subtype (14).
In order to evaluate this directly, we conditionally depleted eosinophils from B6 iPHIL mice, in which 
the diphtheria toxin (DT) receptor is expressed under the control of  the eosinophil peroxidase promoter 
(Supplemental Figure 1C and ref. 15). DT-treated mice or saline-injected controls were challenged with a 
BALB/c lung allograft in the absence of  immunosuppression. Surprisingly, mice depleted of  eosinophils 
had higher grades of  rejection (Figure 1C), increased numbers of  lung-resident T lymphocytes, increased 
rates of  T cell proliferation, and increased effector cell differentiation by day 4 after engraftment (Figure 
1D). These patterns of  T lymphocyte activation and infiltration were especially prominent for CD8+ T cells. 
CD4+ T cell proliferation did increase slightly in the absence of  eosinophils, but the relative proportion of  
CD44hiCD62Llo effector cells did not change (Figure 1D).
To further characterize eosinophil-mediated effects on CD8+ T cells, we transcript profiled lung 
allograft–resident CD8+ T cells in eosinophil-sufficient or eosinophil-depleted mice. Principal compo-
nent analysis (PCA) demonstrated that CD8+ T cells from eosinophil-sufficient or -deficient mice differed 
substantially (Figure 2A). Gene expression analysis demonstrated an upregulation of  2956 and down-
regulation of  2360 genes in the absence of  eosinophils (Supplemental Figure 2A). Using unbiased hier-
archical gene ontology analysis to cluster the 5316 differentially expressed genes, we noted significant 
upregulation of  the inflammatory response, immune system processing, and cell proliferation clusters as 
3 of  the top 4 clusters among the 27 gene ontology groups that differ substantially between lung-resident 
CD8+ T cells in eosinophil-depleted and eosinophil-sufficient mice (Figure 2B and Supplemental Figure 
2B). Taken together, our results show that eosinophils play a unique and unequivocal role in the down-
regulation of  CD8+ T cell–mediated alloimmune responses in the lung allograft. However, mechanistic 
aspects of  CD8+ T cell suppression remain unknown.
Eosinophils suppress T cell responses in a dose-, contact-, and iNOS-dependent manner. In order to further 
define the mechanism(s) of  eosinophil-mediated immunosuppression, we took a reductionist approach 
and cocultured increasing ratios of  E1-polarized eosinophils with B6 T cells in the presence of  anti–CD3/
CD28 polyclonal stimulation for a total of  5 days in vitro. Consistent with our observations in vivo, eosin-
ophils inhibited both proliferation as well as effector differentiation of  CD8+ T cells in a dose-dependent 
manner, even in the absence of  professional antigen-presenting cells (APCs) (Figure 3A). A similar, but less 
pronounced, degree of  inhibition was observed for CD4+ T cells (Supplemental Figure 3A). We next set out 
to define in more detail factors that control eosinophil-mediated T cell regulation. We specifically focused 
on iNOS, based on its upregulation in the lung graft (Figure 1A and ref. 7), as well as physical contact of  
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Figure 1. Th1 polarization of the lung allograft. (A) Seven days after transplantation of BALB/c lung allograft to B6 recipient with or without CSB 
immunosuppression, the whole lung allograft (left) or flow cytometrically sorted lung-resident eosinophils (right) were phenotyped for Th1 or Th2 
polarization using established markers. Comparison was made to E0 resting blood-resident eosinophils (white) or eosinophils polarized to the E1 
(Th1) phenotype by overnight exposure to IFN-γ and TNF-α (yellow) or E2 (Th2) phenotype by overnight exposure to IL-33, IL-4, and GM-CSF (gray). 
Representative of 4 to 6 transplants per group, with Th2 analysis presented in Supplemental Figure 1. (B) Flow cytometric analysis of lung-resident 
eosinophils in BALB/c to B6 lung allografts with (blue) or without (red) CSB. Analysis of eosinophils from resting, untransplanted, B6 lungs shown 
as black line, while isotype control is shaded in gray. Representative of 3 to 5 separate transplants. (C) Histologic and flow cytometric analysis 
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eosinophils with T lymphocytes. We thus cultured B6 T cells with BALB/c dendritic cells (DCs) in the 
presence of  WT eosinophils, iNOS–/– eosinophils, or WT eosinophils separated from T cells by a semi-
permeable transwell, preventing direct T cell–eosinophil contact. Elimination of  either eosinophil iNOS 
expression or eosinophil–T cell interaction ameliorated suppression of  T cell responses (Figure 3B and 
Supplemental Figure 3B). We next extended these experiments by coculturing WT or iNOS–/– eosinophils 
with B6 T cells and BALB/c DCs, but removed eosinophils after 24 hours of  culture. Even after this brief  
period of  interaction, eosinophils still suppressed T cell proliferation (Figure 3C). Taken together, such 
data suggest that eosinophils suppress T cell responses through a contact- and iNOS-dependent mechanism 
early during the course of  the immune response.
Eosinophils suppress T cell responses by altering the integrity of  the TCR/CD3 complex. We next set out to deter-
mine how eosinophil-derived iNOS inhibits T cell activation. Previous work has described that iNOS-elaborated 
mediators such as nitric oxide (NO) and reactive oxygen species (ROS) can initiate T cell death (16), raising 
the possibility that eosinophils may control alloreactivity by altering T cell viability. However the presence of  
eosinophils in in vitro mixed leukocyte reactions (MLRs) did not decrease T cell viability and, surprisingly, 
even enhanced survival (Figure 4A). It has been described that iNOS-expressing, myeloid-derived suppressor 
cells may modify T cell reactivity in a contact-dependent fashion through posttranslational modification of key 
signaling intermediates within the IL-2 signaling pathway (17). IL-2–mediated T cell proliferation, however, was 
not affected upon culture with WT eosinophils (Supplemental Figure 4A).
Alternatively, modulation of  TCR signaling has been described as another mechanism of  iNOS-me-
diated immunoregulation. Specifically, it has been demonstrated that myeloid-derived suppressor cells can 
induce tumor-specific T cell tolerance by interfering with TCR signal transduction and altering the integrity 
of  the TCR in a contact-dependent fashion (18, 19). We thus set out to evaluate signal transduction in 
CD8+ T cells using a system of  green fluorescent protein (GFP) driven by Nr4a1 (Nur77), an early TCR-re-
sponsive gene whose expression directly correlates with the strength of  the TCR signal (20, 21). Indeed, we 
noted a near-complete ablation of  TCR signal transduction in T cells cultured with WT, but not iNOS–/– 
eosinophils (Figure 4B and Supplemental Figure 4B). Further validation through transcriptome analysis of  
CD8+ T cells from lung allografts depleted of  eosinophils demonstrated a similar upregulation of  Nr4a1 
compared with CD8+ T cells from eosinophil-sufficient allografts (Supplemental Figure 4C). To further 
explore this, we evaluated the structural integrity of  the TCR from CD8+ T cells cultured in the presence 
of  WT or iNOS–/– eosinophils utilizing a technique of  immunoprecipitation flow cytometry (IP-FCM) 
recently described by our group (19, 22). We noted that in the presence of  WT but not iNOS–/– eosinophils 
the TCRβ subunit showed decreased association with both CD3ε and CD3ζ, suggesting dissociation of  the 
TCR/CD3 complex. Taken together, our data suggest that eosinophils control T cell responses through 
contact- and iNOS-dependent inhibition of  TCR stability and signal transduction.
Eosinophils mediate T cell suppression through PD-L1–mediated immunological synapse independent of  profes-
sional APCs. Based on our finding that the suppressive capacity of  eosinophils depends on their contact 
with T cells (Figure 3B), we next considered the possibility that professional APCs may act as a scaffolding 
to facilitate eosinophil–T cell contact. This assumption was based on our previous demonstration that T 
cells make stable and durable contact with lung-resident DCs (23) and the fact that eosinophils can medi-
ate the recruitment and accumulation of  DCs in asthma models (24, 25). To this end, we compared in a 
pairwise fashion the formation of  eosinophil–T cell complexes in cocultures of  B6 T cells stimulated with 
BALB/c bone marrow–derived DCs (BMDCs) or anti–CD3/CD28 agonistic antibodies. To our surprise, 
no increase in T cell–eosinophil interaction was evident in the presence of  DCs. In fact, higher numbers 
of  eosinophil–CD8+ T cell complexes formed with CD3/CD28 stimulation (Figure 5A). A similar trend 
was evident for CD4+ T cells, albeit at much lower levels of  cell-to-cell contact (Figure 5A). In addition, the 
frequency of  T cell–eosinophil interactions increased with the duration of  cocultures for both CD8+ and 
CD4+ T cells (Figure 5B). Such data suggested that other factors, such as degree of  T cell activation, may 
be responsible for contact formation.
of BALB/c→iPhil transplants depleted of eosinophils with treatment by DT or saline control. Representative histologic section (top) and ISHLT A 
grade of rejection (bottom).  Scale bar: 100 μm. (D) Total number of graft-resident T cells (top left) and a representative plot of flow cytometrically 
analyzed lung digest defining CD8+ T cells as CD90+CD8+ (top right). Total number of proliferating Ki-67+ T cells (middle left) and a representative 
plot of Ki-67+ CD8+ T cells (middle right). Relative proportion of effector T cells (defined as CD44hiCD62Llo) (bottom left) and a representative plot of 
CD8+ T cell effector differentiation (bottom right). All statistics performed by Mann-Whitney U test. *P < 0.05; **P < 0.01; nsP > 0.05.
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Based on these data, we next evaluated the role of  surface junctional proteins in controlling T cell respons-
es. E1 polarization of  eosinophils specifically upregulated the expression of  CD11b and PD-L1 (Figure 1B 
and Supplemental Figure 5A) but did not affect ICAM-1, -2, or LFA-1 levels (Supplemental Figure 5A). We 
thus initially focused on CD11b based on previous data implicating this integrin in mediating human granulo-
cyte–T cell interactions (26). CD11b blockade, however, did not alter eosinophil–T cell contact (Supplemental 
Figure 5B). We then directed our attention to PD-L1 due to (a) its role in lung allograft tolerance and CD8+ 
T cell differentiation (27), (b) its upregulation during the course of  E0 to E1 polarization (Supplemental 
Figure 5A), (c) the increase of  its ligand PD-1 on lung-resident T cells after transplantation in vivo (Figure 
5C) and in vitro during alloreactivity (Figure 5D), as well as (d) our previous data indicating that PD-L1/
PD-1 interactions control T cell–DC synapse formation in the lung (27). Antibody blockage of  PD-L1/PD-1 
interactions led to a decrease in number of  eosinophil–T cell complexes (Figure 5E) and increased T cell 
proliferation and effector differentiation (Figure 5F and Supplemental Figure 5C). Using ImageStream sin-
gle-cell analysis of  T cell and eosinophil cocultures, we noted that PD-L1 expression on eosinophils was 
highly polarized and predominantly sequestered to the membrane region in contact with T cells (Figure 5G). 
Figure 2. Gene expression analysis of lung allograft–resident CD8+ T cells in the presence or absence of eosinophils. (A) Graphic representation of the 
relationship among samples of the same group and the difference between the 2 groups of samples, based on the principle component analysis of the top 
500 genes, selected by highest row variance. (B) Three of the top gene clusters upregulated in lung allograft–resident CD8+ T cells in eosinophil-deficient B6 
recipients of BALB/c lungs as determined by gene ontology analysis using GeneSCF software. (C) Detailed heatmaps defining the relative levels of the top 15 
genes in the inflammatory response, immune system process, and regulation of cell proliferation pathways defined as part of gene ontology analysis.
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Thus, eosinophils made direct contact with T cells through PD-L1, which was critical for their suppressive 
effect. Of note, CD8+ T cells expressed higher levels of  the PD-L1 receptor PD-1 compared with CD4+ T 
cells (Figure 5, C and D). Such data provide a possible explanation of  why eosinophil-mediated interaction 
and suppression was more pronounced for CD8+ rather than CD4+ T cells. Interestingly, PD-L1 levels were 
similar between WT and iNOS–/– eosinophils (Supplemental Figure 5A), despite the fact that iNOS–/– eosino-
phils were unable to inhibit T cell proliferation (Figure 3B). It is thus unlikely that eosinophil-derived PD-L1 
directly contributes to downregulation of  T cell responses through engagement and signaling via PD-1, but 
rather acts only indirectly by mediating cell to cell interaction.
Eosinophils do not directly inhibit allogeneic professional APCs. In addition to their direct effect on T cell 
activity, the possibility existed that eosinophils may also influence T cell responses by altering the anti-
gen-presenting capacity of  professional APCs. This notion is based on work by us as well as others that 
suggests that E2-polarized eosinophils could modulate APCs to affect Th2 pulmonary immune respons-
es (14, 24, 28). However, in our in vitro MLRs we detected only limited numbers of  DC-eosinophil inter-
actions, similar to the low number of  CD4+ T cell–eosinophil interactions described above (Figure 6A). 
Figure 3. In vitro inhibition of T cells by E1-polarized eosinophils. (A) In vitro mixed leukocyte reactions (MLRs) established using anti–CD3/CD28 
Dynabead stimulation of B6 T cells with varying ratios of E1-polarized B6 eosinophils added to the culture. The graph demonstrates percentage 
proliferation, as defined by the dilution of the CellTrace Violet (CTV) proliferation dye, and effector differentiation, as defined by the percentage of 
CD44hiCD62Llo CD8+ T cells after 5 days of coculture. Representative data from 1 out of 3 similar experiments. (B) Proliferation and effector differenti-
ation of B6 CD8+ T cells stimulated by BALB/c dendritic cells in a coculture with a 2:1 ratio of eosinophils to T cells. For some conditions, WT or iNOS–/– 
eosinophils were added directly to the dendritic cell–T cell cocultures, while in other conditions the eosinophils were separated from the dendritic cell–T 
cell cocultures by a semipermeable membrane. Summary of data shown on the left, and representative flow cytometry plots on the right. Representa-
tive data from 1 out of 3 similar experiments. (C) MLRs, similar to those demonstrated in A were set up with a 2:1 ratio of eosinophils to T cells, except 
E1-polarized eosinophils were removed from the culture after 24 hours (X24 hrs) and T cell proliferation was analyzed on day 5 of the MLR. Summary of 
data shown on the left, and representative flow cytometry plot on the right. All statistics performed by Mann-Whitney U test. **P < 0.01; ***P < 0.001.
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In addition, eosinophils did not alter the maturation of  bone marrow–derived myeloid cells in vitro 
(Supplemental Figure 6A). To further evaluate the role of  eosinophils in controlling myeloid cell acti-
vation in vivo, we next transplanted BALB/c lungs to either DT-treated or control B6 iPHIL mice. Both 
CD11c+CD64+ interstitial macrophages, as well as CD11c+CD103+CD64– dendritic cells, expressed 
higher levels of  MHC I and MHC II and costimulatory markers following eosinophil depletion (Figure 
6B). Such differences in APC maturation, however, were absent in T cell–depleted mice (Figure 6C), 
suggesting that effects of  T cell activation, rather than the direct action of  eosinophils, were respon-
sible for the activation of  myeloid cells. Taken together with the T cell–eosinophil contact data, these 
results show that eosinophil-dependent immunoregulation is primarily due to their direct interactions 
with T cells and not myeloid cells.
Augmenting eosinophil recruitment to the lung downregulates alloimmunity and acute graft rejection. To 
evaluate whether eosinophils could be used as a cellular therapy to downregulate alloimmune respons-
es after pulmonary transplantation, we injected 15 × 106 B6 eosinophils into B6CD45.1+ congenic recip-
ients of  BALB/c lungs at the time of  engraftment. We noted that only limited numbers of  injected 
eosinophils homed to the lung graft, with severe graft rejection and CD8+ T cell effector differentia-
tion despite adoptive transfer (Supplemental Figure 7A). Thus, an alternative approach was needed 
to evaluate the role of  augmented eosinophil migration on alloimmune responses. The chemokines 
eotaxin 1 (CCL11) and eotaxin 2 (CCL24) promote eosinophil migration and homing (29), while IL-5 
promotes eosinophil survival (30). We thus administered a combination of  eotaxin 1, 2, and IL-5 intra-
tracheally (31) to B6 recipients of  BALB/c allografts immediately after as well as 24 hours following 
Figure 4. Eosinophils alter TCR signal transduction. (A) In vitro MLRs established using the coculture of bone marrow–derived BALB/c dendritic cells, 
and B6 T cells with a 2:1 ratio of E1-polarized B6 eosinophils directly added to the culture. T cell viability was determined flow cytometrically after 5 days 
of coculture with no, WT, or iNOS–/– eosinophils as described in the graph. Representative data from 1 out of 3 similar experiments. (B) In vitro MLRs 
established using the coculture of anti–CD3/CD28 Dynabeads with Nur77 T cells and a 2:1 ratio of E1-polarized eosinophils. Nur77-driven GFP expression 
was used as a gauge of TCR stimulation in CD8+ T cells after 36 hours of coculture with no, WT, or iNOS–/– eosinophils. Representative of 1 out of 3 separate 
experiments. (C) Evaluation of the TCR/CD3 complex integrity by quantification of TCRβ immunoprecipitations with coassociated CD3ζ or CD3ε on CD8+ 
T cells isolated from in vitro MLRs in the presence of no eosinophils (gray) versus WT (red line) or iNOS–/– eosinophils (black line). Data representative of 1 
out of 5 mice. All statistics performed by Mann-Whitney U test. ***P < 0.001, nsP > 0.05.
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Figure 5. PD-L1–mediated T cell–eosinophil interaction. (A) In vitro MLRs established using the coculture of bone marrow–derived BALB/c dendritic cells 
or anti–CD3/CD28 Dynabeads, and fluorescently labeled CD8+ and CD4+ B6 T cells with a 2:1 ratio of E1-polarized fluorescently labeled B6 eosinophils. 
Eosinophil–T cell interactions were analyzed using Harmony Software. Yellow circles in the top graphic representation demonstrate Harmony Software–
detected T cell–eosinophil interactions, which are quantitated in graphic form at the bottom. (B) Quantification of T cell–eosinophil interaction during 16 
hours of coculture in vitro as determined by Harmony Software analysis of live confocal microscopy. (C) PD-1 expression in CD4+ and CD8+ T cells of resting 
and transplanted murine lungs in vivo. Graphic representation at the top, and quantification of percentage of T cells expressing PD-1 at the bottom. (D) 
PD-1 expression on T cells in in vitro MLRs stimulated with anti–CD3/CD28 Dynabeads in the presence or absence of WT eosinophils. (E) CD8+ T cell–eosin-
ophil interactions in the presence of PD-L1 blockade during 16 hours of coculture in vitro, as determined by Harmony Software analysis of live confocal 
microscopy. (F) CD8+ T cell proliferation and effector differentiation in the presence or absence of eosinophils and PD-L1 blockade in in vitro MLRs with 
anti–CD3/CD28 Dynabead stimulation. All MLRs in A–F demonstrate 1 experiment from 2 to 3. (G) ImageStream analysis of eosinophil–T cell MLRs for 
surface analysis of PD-L1 expression and polarization. All statistics performed by Mann-Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.001; nsP > 0.05.
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lung transplantation, and evaluated the immune response 7 days later in the absence of  convention-
al immunosuppression or CSB. Compared with saline controls, eotaxin-treated mice manifested less 
inflammation and decreased grade of  rejection using the International Society for Heart and Lung 
Transplantation (ISHLT) A Grade criteria (Figure 7A). Eotaxin and IL-5 administration resulted in 
higher numbers of  graft-resident eosinophils (Figure 7B). Although the total number of  CD8+ T cells 
in the lung graft did not change, there were significantly fewer CD8+CD44hiCD62Llo effector cells in 
eotaxin/IL-5–treated lungs (Figure 7C and Supplemental Figure 7B). Eotaxin/IL-5–mediated immu-
nosuppression was not evident in eosinophil-depleted mice (Supplemental Figure 7C), indicating that 
this regimen was not directly immunosuppressive on T cells, but relied on eosinophil migration for its 
function. Collectively, our data suggest that augmenting eosinophil accumulation can be utilized to 
downregulate lung alloimmune responses.
Figure 6. Eosinophil interaction with and phenotypic alter-
ation of myeloid cells. (A) In vitro MLRs established using 
the coculture of fluorescently labeled bone marrow–derived 
BALB/c dendritic cells, and fluorescently labeled CD8+ and 
CD4+ B6 T cells with a 2:1 ratio of E1-polarized fluorescently 
labeled B6 eosinophils. Eosinophil–T cell–dendritic cell inter-
actions were analyzed using Harmony Software, with the 
yellow circles in the top graphic representing interactions. 
The bottom panel represents the number of eosinophil 
contacts with CD4+ T cells, CD8+ T cells, or dendritic cells. 
Data representative of 2 separate experiments. (B) BALB/c 
lungs were engrafted into B6 iPHIL mice treated with DT 
(eosinophil deficient) or saline (eosinophil sufficient). The 
phenotypes of CD11c+CD64+ interstitial macrophages and 
CD103+ dendritic cells were evaluated flow cytometrically in 
engrafted lungs in the presence of the full complement of T 
lymphocytes (left panels) or after depletion of both CD4+ and 
CD8+ T cells (right panel). Representative of 2 separate sets 
of transplants. All statistics performed by Mann-Whitney U 
test. ***P < 0.001.
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Discussion
Unlike other solid organ allografts, lungs are unique, as they are continuously exposed to the external envi-
ronment as part of  their natural function of  gas exchange. For these reasons, unique pulmonary-specific 
immunoregulatory pathways have developed to eliminate environmental pathogens while resolving benign 
nonpathogenic insults. Pathways for rapid downregulation of  inflammatory responses have also evolved 
out of  necessity to ameliorate undue damage to bystander pulmonary parenchyma during the course of  
the immune response. Eosinophils are bone marrow–derived granulocytes that are known for their ability 
to combat infection and are found in low levels at baseline in healthy lungs (14). Both experimental and 
clinical eosinophil deficiency renders hosts more susceptible to infectious disease, especially by fungal and 
parasitic organisms (32, 33). Consistent with these IL-4–dominated parasitic Th2 responses, eosinophils 
have also been well described to contribute to the initiation, propagation, and possibly resolution of  allergic 
environmental asthma (34). While the role of  eosinophils in other immunologic processes is still under 
investigation, here we identify that in the setting of  lung transplantation, eosinophils may function similarly 
to granulocytic myeloid-derived suppressor cells by downregulating T cell immune responses through the 
modification of  TCR/CD3 stability and signal transduction (18, 19).
Current clinical status of  solid organ transplantation involves the use of  global immunodepleting or 
immunosuppressive drugs. Standard protocols for surveillance have been designed to diagnose inflam-
matory changes through routinely scheduled biopsies of  grafts (1). Any increase in inflammation is 
treated through upregulation of  immunosuppression to combat what is considered early rejection (1). 
Figure 7. Rejection of BALB/c→B6 lung grafts treated with intratracheal eotaxin 1, 2, and IL-5. BALB/c lungs were transplanted into B6 recipients, which were 
treated with an intratracheal chemokine and cytokine cocktail of eotaxin 1, 2, and IL-5 immediately after engraftment and 1 day after transplantation. Lung grafts 
were evaluated flow cytometrically and histologically after 7 days for rejection (A), total eosinophil content (B), and CD8+ T cell differentiation (C). Histologic anal-
ysis for ISHLT grade of rejection was performed on slides stained with hematoxylin and eosin (H&E), and eosinophil peroxidase immunohistochemistry was per-
formed to evaluate eosinophil orientation in the tissue (eosinophils stained red). Scale bars: 100 μm. All statistics performed by Mann-Whitney U test. *P < 0.05.
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For these reasons, eosinophil-related inflammatory changes and organ infiltration have been proposed 
as both a mediator and diagnostic feature of  liver allograft rejection (35). In direct contrast to this 
notion, we have demonstrated that proinflammatory feedback loops, of  which eosinophils are a critical 
component, play a critical role in tolerance induction in the lung (7). Disruption of  such loops, through 
depletion of  either CD8+ T cells or eosinophils, prevents CSB-mediated graft acceptance (5, 7). Here 
we extend those findings to describe that eosinophils contribute to the downregulation of  lung allograft 
rejection even in the absence of  immunosuppression. Our data thus solidify the role of  eosinophils as 
an exclusive and, we believe, previously unrecognized regulatory leukocyte in the lung. Based on these 
data, as well as on select human observational studies, it is possible that eosinophils may play a similar 
immunosuppressive role in other organ transplants (36). Furthermore, recent data from the University 
of  Zurich by Arnold and colleagues demonstrate that eosinophils may interfere with Th1-mediated 
clearance of  gastrointestinal pathogens (37). It is thus possible that the eosinophils may downregulate 
immune responses across multiple disease processes.
We also demonstrate in our system that eosinophils interfere with TCR stability and signal transduction 
as their mechanism of  immunosuppression. In this manner, eosinophil-mediated immunoregulation in the 
lung allograft mirrors that of  malignancy-related immunosuppression, where multiple mechanisms function 
to downregulate TCR signaling and mediate tumor escape (18, 19). This finding also creates an appealing 
aspect for tolerance induction, as eosinophils can effectively alter the “priming” phase of  alloreactivity that 
occurs immediately after engraftment. Since eosinophils accumulate in the allograft early after engraftment 
(7), they affect allorecognition at early time points and may alter the frequency of  alloreactive T cell clones 
for the life of  the graft. By interfering with the strength of  TCR signal transduction, eosinophil-mediated 
downregulation of  immune responses may mirror CSB shaping of  the T cell repertoire toward lower-affinity 
clones (38). It is thus possible that such early action may indirectly affect long-term immunologic graft sur-
vival. Whether eosinophils are critical or dispensable at later time points in the lung has yet to be resolved.
Despite the ever-growing appreciation of  inhibitory ligand-receptor interactions in cancer (39), the bio-
logical role of  PD-L1 in transplant tolerance is just now being appreciated. Our data thus support the early 
reports by Tanaka and colleagues demonstrating that PD-L1 expression plays a role in tolerance induction of  
cardiac allografts (40). A recent report from our group that PD-1 blockade can break lung allograft tolerance 
supports this notion as well (27). Interestingly, we now describe that PD-1/PD-L1 interactions increase the 
number of  T cell–eosinophil contacts (Figure 5E). This is in direct contrast to the case for CD11c+ DCs, where 
PD-L1/PD-1 interactions actually decreased T cell dwell time (27). Taken together, our results suggest that 
T cell PD-1 expression plays a dual role in facilitating lung allograft tolerance by both decreasing interaction 
with prorejection APCs such as CD11c+ DCs, while at the same time augmenting contact with regulatory 
cells such as eosinophils. Since iNOS–/– eosinophils still express PD-L1 upon E0 to E1 polarization (Supple-
mental Figure 5A), we can assume that, at least in our model, eosinophil expression of  PD-L1 contributes to 
cell-cell interactions and not to direct inhibition of  T cell activation through PD-1 engagement. This finding 
sets PD-L1–dependent allograft tolerance apart from some models of  tumor-related immunosuppression, 
where direct signaling through PD-1 leads to downregulation of  the T cell responses (41). However, our data 
support other models where PD-L1 expression correlates with, but does not directly contribute to, the down-
regulation of  T cell function through PD-1 engagement (42). Thus, our data extend the notion that the role of  
PD-L1 in immune suppression must be APC and context dependent.
While PD-L1/PD-1 seems to control cell contact, our data further support the dominant and near-ex-
clusive role of  iNOS in eosinophil-mediated downregulation of  immune responses. The observation that 
both contact and iNOS expression determines eosinophil-specific inhibition of  T cell proliferation (Figure 
3B) further strengthens the notion that environmental polarization of  eosinophils is critical for their sup-
pressive function. It is important to point out that in the absence of  exogenous Th1-polarizing cytokines, 
such as IFN-γ and TNF-α, neither PD-L1 nor iNOS is expressed in E0 unpolarized resting eosinophils 
(Figure 1, A and B, and Supplemental Figure 5A). Only upon polarization to the E1 phenotype do such 
suppressive mediators become evident (Supplemental Figure 5A). IL-4– and IL-33–polarized E2 eosino-
phils also do not express iNOS (Figure 1, A and B), furthering the notion that the environmental context 
controls eosinophil-mediated immunoregulation in our system.
Unlike the case for most other organs, where access for local drug delivery can be problematic, intratra-
cheal administration of  biological mediators can readily be utilized to alter the course of  pulmonary immune 
responses (43, 44). Based on this notion, we now demonstrate that local administration of  eosinophil-specific 
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chemokines and cytokines can alter lung allograft rejection in an eosinophil-dependent fashion. Such data 
open the possibility of  accentuating naturally occurring tolerogenic feedback loops in order to downregulate 
lung graft rejection in the absence of  global nonspecific immunosuppression.
Methods
Animals
C57BL/6CD45.2+ (B6) (H2b), B6.SJL/BoyJ(B6CD45.1+) (H2b), BALB/c (H2d), and Nur-77 GFP (C57BL/6-Tg(N-
r4a1EGFP/cre)820Khog/J) mice were obtained from The Jackson Laboratory. iPHIL mice (expressing 
the DT receptor under the control of  an eosinophil peroxidase–specific promoter) and hypereosinophilic 
IL-5–transgenic mice (NJ.1638) were developed in our laboratory at the Mayo Clinic (15, 45), and bred 
and maintained at the vivarium facility at the University of  Virginia School of  Medicine. For in vitro 
experiments, iNOS–/– hypereosinophilic mice were generated by crossing the NJ1638 strain with the 
B6.129P2-Nos2tm1Lau/J (iNOS–/–) strain (Jackson Laboratory) for at least 3 generations. Such mice were then 
maintained as a colony by crossing the NJ1638 iNOS–/– strain with WT iNOS–/– mice. The animals passed 
all necessary genotyping screening or quarantine serological tests (for those that were transported from 
one university to the other) before they were used in this study. Mice used as donors were 5- to 8-week-old 
males; those used as graft recipients in this study were also males at 2 to 4 months of  age, while both male 
and female hypereosinophilic mice were used when they were 3 to 7 months old for eosinophil isolation.
Surgery and transplantation
Orthotopic transplantation of  a left lung allograft was carried out according to our previous reports (46, 
47). To achieve allograft acceptance, mice were treated with double costimulatory blockade of  the CD28/
B7 and the CD40/CD40L pathways as previously described (48).
Histology
Lungs were fixed in formalin, sectioned, and stained with hematoxylin and eosin (H&E). A lung patholo-
gist blinded to the experimental conditions graded graft rejection using standard criteria (ISHLT A Grade, 
developed by the Lung Rejection Study Group (49).
Immunohistochemistry
Formalin-fixed lung tissues embedded in paraffin were sectioned, subjected to antigen retrieval, and stained 
with either mouse anti–mouse eosinophil peroxidase and secondary goat anti-mouse antibodies or rat 
anti–mouse CD8 and secondary donkey anti-rat antibodies for the detection of  eosinophils or CD8+ cells, 
respectively, as previously reported (50, 51). The protocol for eosinophil detection included blocking with 
Dual Endogenous Blocking Solution (Dako) and donkey serum before incubation in the primary antibody, 
while horse serum was used for the initial blocking of  the tissue slide for CD8 staining and detection.
Flow cytometry
For flow cytometric analysis, lung tissue derived from resting or graft recipient mice was well minced with 
scissors and digested by placing it into RPMI 1640 medium (Thermo Fisher Scientific) containing 0.5 mg/ml 
collagenase II (Worthington Biochemical Corporation) and 5 U/ml DNAse (Sigma-Aldrich) for 60 minutes at 
37°C in a shaker. The digested lung tissue was passed through a 70-μm cell strainer and treated with ACK lys-
ing buffer (Lonza) to remove red cell contamination. This digestion method has been previously described (7).
Measuring the subunit ratios within the TCR/CD3 complex via IP-FCM was performed as previously 
described (19). Briefly, CD8+ T cells were purified from a 36-hour culture where T cells were activated by 
plate-bound CD3/CD28 in the presence of  no eosinophils, WT eosinophils, or iNOS–/– eosinophils. For 
evaluation of  the TCR complex, the CD8+ T cells were lysed in 1% digitonin isotonic lysis buffer, and 
postnuclear lysates were incubated for IP with a monoclonal antibody specific for TCRβ (clone H57-597) to 
immunoprecipitate the native TCR/CD3 complexes. With the β chain functioning to pull down the TCR, 
such captured complexes were then probed in parallel with PE-conjugated monoclonal antibodies specific 
for CD3ζ (clone 6B10) or CD3ε (clone 2C11) for evaluation of  TCR complex integrity.
All antibodies for flow cytometry were primarily fluorochrome-conjugated anti-mouse monoclo-
nal antibodies, mostly derived from rat. Thus, staining of samples was by direct immunofluorescence. 
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Intracellular staining was performed as previously described (7). The following antibodies were purchased from 
BD Biosciences: anti-iNOS FITC (clone 6/iNOS/NOS type II), anti–PD-L1 PE or brilliant violet (BV)-421 
(clone MIH5), and anti–Siglec-F PE or PerCPCy5.5 (clone E50-2440). Antibodies purchased from Biolegend 
include anti-CD68 Alexa-488 or BV-421 (clone FA-11); anti-CD206 FITC, APC, or BV-421 (clone C068C5); 
anti-CD64 PE-Cy7 (clone X54-5/7.1); and anti-CCR3 PE or PE-Cy7 (clone J073E5). The following antibod-
ies were purchased from Thermo Fisher Scientific–eBiosciences: anti-CD45 eFluor-450 or eFluor-506 (clone 
30-F11); anti-CD45.2 eFluor-450 or eFluor-506 (clone 104); anti-CD45.1 APC-eFluor-780 or eFluor 506 (clone 
A20); anti-CD11b FITC or APC-eFluor-780 (clone M1/70); anti-CD86 PE or PE-Cy7 (clone GL1); anti-
CD80 APC or PE-Cy7 (clone 16-10A1); anti–MHC-II (IA/IE) APC-eFluor-780 (clone M5/114.15.2); anti-
CD8a FITC, PerCPCy5.5, or APC-eFluor-780 (clone 53-6.7); anti-CD90.2 FITC or APC-eFluor-780 (clone 
Thy-1.2); anti-MHC-I (H2Kb) PE or APC (clone AF6-88.5.5.3); anti-MHC-I (H2Kd) PerCP-eFluor710 (clone 
SF1-1.1.1); anti–MHC-II (IA/IE) Alexa-488 (clone M5/114.15.2); anti–MHC-II (IA-b) PE (clone AF6-120.1); 
anti–MHC-II (IA-d) APC (clone AMS-32.1); anti-CD11c PerCPCy5.5 or eFluor-506 (clone N418); anti-F4/80 
FITC or PE (clone BM8); CD103 eFluor 450 (clone 2E7); anti–PD-1 APC (clone J43); anti-CD40 APC (clone 
1C10); anti-CD4 APC or eFluor 405 (clone RM4-5); anti-CD44 PE or PerCPCy5.5 (clone IM7); anti-CD62L 
PE-Cy7 (clone MEL-14); anti-CD101 PE (clone Moushi101); and anti–Ki-67 PE (clone SolA15). All fluoro-
chrome-conjugated antibodies were matched with the corresponding IgG isotypes as antibody controls. In 
addition, fluorescence-minus-one (FMO) controls were also used to separate the negative and positive popula-
tions. Dead cells were excluded with Live/Dead Fixable Stain (Thermo Fisher Scientific). To block nonspecific 
binding to Fc receptors, we used anti–CD16/CD32 (Thermo Fisher Scientific) (clone 93). Cells expressing 
various markers of interest were acquired in a BD FACSCanto II, equipped with 3 lasers for 10-parameter 
detection (BD Biosciences). Quality controls were performed daily on the flow cytometers according to the 
manufacturer’s instructions. Analysis of flow cytometry data was done with FlowJo software, version 10.
Image cytometry
ImageStream Mark II (MilliporeSigma) was used to visualize and study immune synapse formation 
between eosinophils and T cells. The procedure is as previously reported (52), with slight modifications. 
Briefly, a combination of  purified T cells (stimulated with DCs or anti–CD3/CD28 agonistic antibodies) 
and eosinophils were incubated for 24 hours to establish contacts. Cells were washed in 2% FBS in PBS 
and centrifuged at 200 g for 4 minutes. Cells were fixed with BD Cytofix (Fixative Buffer) for 20 minutes 
and washed with BD Perm/Wash buffer at 200 g for 4 minutes. Cells were stained with a combination of  
rat anti-mouse antibodies, including anti-CD8 FITC (clone 53-6.7), anti–PD-L1 PE (clone MIH5), and 
anti–Siglec-F PerCpCy5.5 (clone E50-2440), and incubated for 30 minutes at 4°C. The cells were washed 
in BD Perm/Wash buffer at 200 g for 4 minutes and resuspended in 2% FBS in PBS for acquisition. The 
image data were visualized and analyzed with the Ideas Software version 6.
Fluorescence-activated cell sorting for lung eosinophils
Eosinophils were sorted as CD45+CD11b+Siglec-F+CD11c– cells following the staining of  digested lungs 
with a panel of  fluorochrome-conjugated antibodies similar to the ones used for flow cytometry. Sorting 
was done using the BD Influx (BD Biosciences).
Isolation, culture, and polarization of mouse peripheral blood eosinophils
Eosinophils were isolated from peripheral blood of  NJ.1638 or NJ1638 iNOS–/– strain after density-de-
pendent separation of  the eosinophil-rich white blood cells using a combination of  Histopaque 1119 and 
1083 (Sigma-Aldrich) at a ratio of  1:9, followed by negative selection of  a greater than 98% pure eosinophil 
population after incubation of  white blood cells with a combination of  CD45R/B220 and CD90.2/Thy-
1.2 immunomagnetic beads (Miltenyi Biotec). The purity of  eosinophils was confirmed by flow cytometry 
(CD45+CD11b+Siglec-F+CD11c– cells). The details of  the cell preparation and eosinophil purification pro-
tocol are as we have previously described (9). For in vitro experiments, purified eosinophils were cultured at 
5 × 105/ml for 18 to 24 hours in RMPI-1640 media (containing glutamine and 25 mM HEPES) (Thermo 
Fisher Scientific) supplemented with 10% FBS, 10 U/ml penicillin, 10 μg/ml streptomycin, 29.2 μg/ml 
L-glutamine, and 55 μM β-mercaptoethanol. Eosinophils maintained in an unpolarized (E0) state were 
cultured with 10 ng/ml IL-5. Th1-polarized eosinophils (E1) were cultured with 10 ng/ml IL-5, 15 ng/
ml IFN-γ, and 15 ng/ml TNF-α, while Th2-polarized eosinophils (E2) were cultured with 10 ng/ml IL-5, 
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30 ng/ml IL-33, 10 ng/ml IL-4, and 10 ng/ml GM-CSF. All cytokines and growth factors used for eosino-
phil polarization culture were recombinant proteins purchased from Peprotech.
In vitro MLR
BMDCs (53) from BALB/cJ mice or anti–CD3/CD28 agonistic antibodies (Dynabeads or plate bound, 
Thermo Fisher Scientific) were used to stimulate Thy1.2-positive (CD90.2-positive) cells from B6, 
B6.SJL/BoyJ, or Nur77GFP mouse splenocytes. After careful titration, the volume of  Dynabeads used 
was 5.0 μl for 1 ml of  media containing 1 × 106 T cells. Such concentration resulted in 50% to 90% T cell 
proliferation after 5 days of  culture. To prepare the coated plate used for a maximum of  48 hours of  cul-
ture, the concentration of  soluble anti–CD3/CD28 agonistic antibodies used were 2.0 μg/ml anti-CD3 
and 1.0 μg/ml anti-CD28 agonistic antibodies in PBS. A small volume (250 μl) of  the solution was used 
to coat 1 well of  a 96-well round-bottom plate. The CD90.2+ cells were obtained by positive selection 
with magnetic-activated cell separation (MACS) using Mouse CD90.2 MicroBeads (Miltenyi Biotec). In 
some experiments, where we needed to reisolate CD8+ T cells from the MLRs after culture, T cells were 
isolated from the splenocytes by negative selection using Mouse Pan T Cell Isolation Kit II (Miltenyi 
Biotec). CD90.2+ cells or purified T cells were cultured together with the BMDCs in a round-bottom 
96-well plate at a ratio of  10:1 (T cells/BMDCs). In some experiments, eosinophils isolated from NJ1638 
or NJ1638 iNOS–/– mice were also added to the culture at 2:1 eosinophil/T cell ratio or as stated in the 
results section. Cells were cultured at 37°C with addition of  5% carbon dioxide. Proliferation of  the T 
cells was analyzed flow cytometrically based on Ki-67 expression or dilution of  CellTrace Violet (CTV) 
after 3 or 5 days of  culture as described in the text.
In vitro antibody–mediated protein neutralization
CD11b and PD-L1 were neutralized in vitro using 20 μg/ml of  rat anti–mouse/human CD11b (clone 
M1/70) and 20 μg/ml rat anti–mouse PD-L1 (clone 10F.9G2) (Bio X Cell), respectively. The proteins were 
added to the culture on set-up days.
Confocal microscopy for live cell imaging
T cells, eosinophils, and DCs were separately labeled with a single-fluorochrome cell surface antibody 
specific for each population or marker of  interest at 20 μl of  each antibody per 5 × 106 cells in 200 μl of  the 
staining solution containing 2% FBS in PBS. Cells were incubated at 4°C and washed in the staining solu-
tion before they were added to the MLR in a 96-well plate as follows: 5 × 105 T cells, 5 × 105 eosinophils, 
and 1 × 105 DCs (when required). The rat anti-mouse antibodies used include: anti-CD8 FITC (clone 
53-6.7) (Thermo Fisher Scientific), anti–Siglec-F PE (clone E50-2440), anti-CD4 Alexa-647 or BV 421 
(clone RM4-5), anti-CD11b BV-421 (clone M1/70), and anti-CD11c BV-421 (clone N418) (BD Biosci-
ences). Cells were cultured for 4 hours in the incubator at 37°C and 5% carbon dioxide before the cultures 
were transferred into the confocal microscope, Operetta CLS (PerkinElmer), where the initial incubation 
conditions (37°C and 5% carbon dioxide) were also maintained during live cell imaging and data acquisi-
tion. Data acquisition and analysis were done with Harmony Software, version 4.5 (PerkinElmer). To ana-
lyze eosinophil–T cell or eosinophil-DC contacts, the outer border of  each cell population was established 
and a contact/fluorescence threshold was set after inspection based on the nearness or overlap of  cells to 
one another and measured as the intensity of  detection of  the fluorochrome signal of  1 cell in another cell 
type. All cells separated by lower distances than the threshold were captured by the Harmony Software.
Eosinophil ablation
Eosinophils were ablated in iPHIL mice through intraperitoneal administration of  DT (MilliporeSigma) 
as we previously described (15). DT was reconstituted in PBS and administered at a dose of  15 ng/gm 
of  mouse 5, 4, and 3 days before transplantation, and 1 day after transplantation. Control mice received 
equivalent volume of  vehicle.
In vivo antibody-mediated cytokine neutralization
All neutralization antibodies are of  rat origin and purchased from Bio X Cell. For the targeted depletion 
of  eosinophils in allograft recipients, 200 μg of  anti–mouse/human IL-5 (clone TRFK5) was adminis-
tered to each mouse 2 days and 1 day before transplantation, and 1 day and 2 days after transplantation. 
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For the depletion of  T cells, 200 μg each of  anti–mouse CD4 (clone GK 1.5) and anti–mouse CD8 
(clone YTS 169.4) were administered together in a cocktail to each mouse 3 days and 1 day before 
transplantation, and 1 day after transplantation. Each control animal for all the antibody-mediated cell 
depletion experiments received an equivalent concentration of  rat IgG control (clone HRPN).
In vivo eosinophil mobilization
This was achieved through the intratracheal administration of  a combination the following recombinant 
proteins purchased from Peprotech: 3 μg recombinant mouse CCL11 (eotaxin), 3 μg recombinant mouse 
CCL24 (eotaxin 2), and 1 μg recombinant mouse IL-5 to each graft recipient immediately after transplant 
and 1 day after transplant. The chemokine/cytokine combination was given in 100 μl intratracheally.
Quantitative polymerase chain reaction
RNA was extracted from lung digests, and eosinophils were isolated from the lung or in vitro polarized eosin-
ophils using the TRIzol-based technique according to the manufacturer’s guidelines (Thermo Fisher Scien-
tific). cDNA was reverse transcribed from RNA samples using the High-Capacity cDNA Reverse Transcrip-
tion Kit in accordance with the manufacturer’s instruction (Thermo Fisher Scientific–Applied Biosystem). 
Quantitative PCR (qPCR) was performed on the cDNA samples using Power SYBR Green PCR Master 
Mix (Thermo Fisher Scientific–Applied Biosystem) in a CFX-96 Real-Time PCR Detection System (Bio-
Rad). Cycling and reaction conditions were as provided by the manufacturer. The primers used are as fol-
lows (FW, forward; RV, reverse): IFN-γ FW: ATGAACGCTACACACTGCATC, RV: CCATCCTTTTGC-
CAGTTCCTC; TNF-α FW: CCCTCACACTCAGATCATCTTCT, RV: GCTACGACGTGGGCTACAG; 
IL-5 FW: CTCTGTTGACAAGCAATGAGACG, RV: TCTTCAGTATGTCTAGCCCCTG; IL-33 FW: 
TCCAACTCCAAGATTTCCCCG, RV: CATGCAGTAGACATGGCAGAA; IL-4 FW: GGTCTCAAC-
CCCCAGCTAGT, RV: GCCGATGATCTCTCTCAAGTGAT; GM-CSF FW: GGCCTTGGAAGCAT-
GTAGAGG, RV: GGAGAACTCGTTAGAGACGACTT; iNOS FW: GTTCTCAGCCCAACAATA-
CAAGA, RV: GTGGACGGGTCGATGTCAC; β-actin FW: CGTGCGTGACATCAAAGAG, RV: 
TGCCACAGGATTCCATAC; CCL17 FW: TACCATGAGGTCACTTCAGATGC, RV: GCACTCTCG-
GCCTACATTGG; IL-13 FW: CCTGGCTCTTGCTTGCCTT, RV: GGTCTTGTGTGATGTTGCTCA; 
CXCL9 FW: GGAGTTCGAGGAACCCTAGTG, RV: GGGATTTGTAGTGGATCGTGC; CXCL10 FW: 
CCAAGTGCTGCCGTCATTTTC, RV: GGCTCGCAGGGATGATTTCAA; CXCL11 FW: GGCTTCCT-
TATGTTCAAACAGGG, RV: GCCGTTACTCGGGTAAATTACA; CCL22 FW: AGGTCCCTATGGT-
GCCAATGT, RV: CGGCAGGATTTTGAGGTCCA.
RNA-Seq gene expression analysis
Sample preparation and RNA extraction. RNA was extracted from CD8+ T cells isolated from left lung allografts 
of either eosinophil-depleted or -nondepleted B6 recipients of BALB/c left lung grafts 4 days after transplanta-
tion, using the TRIzol-based technique according to the manufacturer’s guidelines (Thermo Fisher Scientific).
RNA library preparation via polyA selection and multiplexing of  Mus musculus. RNA samples were quanti-
fied using Qubit 2.0 Fluorometer (Thermo Fisher Scientific–Life Technologies), and RNA integrity was 
checked with 2100 Bioanalyzer (Agilent Technologies). RNA library preparations, sequencing reactions, 
and initial bioinformatics analysis were conducted at GENEWIZ, LLC.
RNA sequencing (RNA-Seq) library preparation used the NEBNext Ultra RNA Library Prep Kit for 
Illumina by following the manufacturer’s recommendations (NEB). Briefly, mRNA was first enriched 
with oligo d(T) beads. Enriched mRNAs were fragmented for 15 minutes at 94°C. First-strand and sec-
ond-strand cDNA were subsequently synthesized. cDNA fragments were end repaired and adenylated at 
the 3′ ends, and universal adapter was ligated to cDNA fragments, followed by index addition and library 
enrichment with limited-cycle PCR. Sequencing libraries were validated using a DNA Chip on the Agilent 
2100 Bioanalyzer (Agilent Technologies) and quantified by using Qubit 2.0 Fluorometer (Thermo Fisher 
Scientific–Invitrogen) as well as by qPCR (Thermo Fisher Scientific–Applied Biosystems).
Sequencing. The sequencing libraries were multiplexed and clustered onto a flow cell. After clus-
tering, the flow cell was loaded on the Illumina HiSeq 4000 or equivalent instrument according to the 
manufacturer’s instructions. The samples were sequenced using a 2 × 150 bp paired-end configuration. 
Image analysis and base calling were conducted by the HiSeq Control Software (HCS) on the HiSeq 
instrument. Raw sequence data (.bcl files) generated from Illumina HiSeq were converted into fastq 
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files and demultiplexed using Illumina bcl2fastq v 2.17 program. One mismatch was allowed for index 
sequence identification.
RNA-Seq analysis. After investigating the quality of  the raw data, sequence reads were trimmed to 
remove possible adapter sequences and nucleotides with poor quality using Trimmomatic v.0.36. The 
trimmed reads were mapped to the Mus musculus reference genome available on ENSEMBL using the 
STAR aligner v.2.5.2b. The STAR aligner uses a splice aligner that detects splice junctions and incorporates 
them to help align the entire read sequences. BAM files were generated as a result of  this step. Unique gene 
hit counts were calculated by using feature counts from the Subread package v.1.5.2. Only unique reads that 
fell within exon regions were counted. Since a strand-specific library preparation was performed, the reads 
were strand-specifically counted.
After extraction of  gene hit counts, the gene hit counts table was used for downstream differential 
expression analysis. Using DESeq2, a comparison of  gene expression between the groups of  samples was 
performed. The Wald test was used to generate P values and log2 fold changes. Genes with adjusted P val-
ues less than 0.05 and absolute log2 fold changes greater than 1 were called as differentially expressed genes 
for each comparison. A gene ontology (GO) analysis was performed on the statistically significant set of  
genes by implementing the software GeneSCF. The mgi GO list was used to cluster the set of  genes based 
on their biological process and determine their statistical significance. A PCA analysis was performed using 
the “plotPCA” function within the DESeq2 R package. The plot shows the samples in a 2D plane spanned 
by their first 2 principal components. The top 500 genes, selected by highest row variance, were used to 
generate the plot. The RNA-Seq data have been stored at https://figshare.com/s/e6c0df2faacdf1ffb306. 
The data can also be located through DOI: 10.6084/m9.figshare.7910444.
Statistics
Friedman’s test was used for paired data, while the Kruskall-Wallis test was used for unpaired group of  obser-
vations. Post hoc analysis of  differences and comparison of  differences between pairs of  data were done with 
the Wilcoxon rank test and the Mann-Whitney U test for paired and unpaired observations, respectively. 
Differences were considered significant at P < 0.05. Differences in RNA-Seq analysis between the test and 
control groups were further considered significant at an adjusted P value < 0.05. The primary outcome mea-
sures are presented in scatter or dot plots. For the scatter plots, the inner dark line represents the mean value 
while the whiskers above and below the mean represent the standard error of  mean. For the box plots, the 
bottom and top of  the boxes represent the lower and upper quartiles respectively, the dark band inside the box 
represents the median, while the top and bottom whiskers represent the maximum and minimum observed 
values respectively. Data analysis and preparation of  figures were done with GraphPad Prism 7.0b software.
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